DOCSLIB.ORG

(MONALEESA-3): a Randomized Double-Blind, Placebo-Controlled

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(MONALEESA-3): a Randomized Double-Blind, Placebo-Controlled Clinical Development LEE011 (ribociclib) Protocol CLEE011F2301 / NCT02422615 MONALEESA-3: A randomized double-blind, placebo- controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment Authors Document type Amended Protocol Version (Clean) EUDRACT number 2015-000617-43 Version number 02 (Amended Protocol) Development phase III Document status Final Release date 28-Jul-2016 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Template version 17-Nov-2014 Novartis Confidential Page 2 Amended Protocol Version 02 (Clean) Protocol No. CLEE011F2301 Table of contents Table of contents ................................................................................................................. 2 List of figures ...................................................................................................................... 6 List of tables ........................................................................................................................ 6 List of abbreviations ............................................................................................................ 8 Glossary of terms ............................................................................................................... 11 Amendment 2 (28-Jul-2016) ............................................................................................. 13 Amendment 1 .................................................................................................................... 16 Protocol summary: ............................................................................................................. 21 1 Background ........................................................................................................................ 26 1.1 Overview of disease pathogenesis and current treatment ...................................... 26 1.1.1 Epidemiology ........................................................................................ 26 1.1.2 Available therapeutic options in ER+, HER2-negative breast cancer .................................................................................................... 26 1.1.3 Role of the CDK4/6 pathway in breast cancer ...................................... 27 1.2 Introduction to investigational treatment(s) and other study treatment(s) ............. 28 1.2.1 Overview of ribociclib .......................................................................... 28 1.2.2 Overview of fulvestrant ......................................................................... 34 1.2.3 Overview of ribociclib in combination with fulvestrant ....................... 36 2 Rationale ............................................................................................................................ 37 2.1 Study rationale and purpose ................................................................................... 37 2.2 Rationale for the study design ............................................................................... 38 2.3 Rationale for dose and regimen selection .............................................................. 39 2.4 Rationale for choice of combination drugs ............................................................ 39 2.5 Rationale for choice of comparator drugs ............................................................. 40 2.6 Risks and benefits .................................................................................................. 40 2.6.1 Potential benefits to clinical trial participants ....................................... 40 2.6.2 Potential risks to clinical trial participants ............................................ 40 3 Objectives and endpoints ................................................................................................... 41 4 Study design ...................................................................................................................... 44 4.1 Description of study design ................................................................................... 44 4.1.1 Screening phase ..................................................................................... 46 4.1.2 Treatment phase .................................................................................... 46 4.1.3 Safety follow-up .................................................................................... 46 4.1.4 Efficacy follow-up ................................................................................ 47 4.1.5 Survival follow-up ................................................................................ 47 4.2 Timing of interim analyses and design adaptations ............................................... 47 Novartis Confidential Page 3 Amended Protocol Version 02 (Clean) Protocol No. CLEE011F2301 4.3 Definition of end of the study ................................................................................ 47 4.4 Early study termination .......................................................................................... 48 5 Population .......................................................................................................................... 48 5.1 Patient population .................................................................................................. 48 5.2 Inclusion criteria .................................................................................................... 48 5.3 Exclusion criteria ................................................................................................... 50 6 Treatment ........................................................................................................................... 52 6.1 Study treatment ...................................................................................................... 52 6.1.1 Dosing regimen ..................................................................................... 53 6.1.2 Guidelines for continuation of treatment .............................................. 55 6.1.3 Ancillary treatments .............................................................................. 55 6.1.4 Rescue medication ................................................................................ 55 6.1.5 Treatment duration ................................................................................ 55 6.2 Dose escalation guidelines ..................................................................................... 55 6.3 Patient numbering, treatment assignment or randomization ................................. 55 6.3.1 Patient numbering ................................................................................. 55 6.3.2 Treatment assignment or randomization ............................................... 56 6.3.3 Treatment blinding ................................................................................ 56 6.4 Study drug preparation and dispensation ............................................................... 57 6.4.1 Study drug packaging and labeling ....................................................... 57 6.4.2 Drug supply and storage ........................................................................ 58 6.4.3 Study drug compliance and accountability ........................................... 58 6.4.4 Disposal and destruction ....................................................................... 58 6.5 Dose modifications ................................................................................................ 59 6.5.1 Dose modification and dose delay ........................................................ 59 6.5.2 Follow-up for toxicities ......................................................................... 66 6.5.3 Anticipated risks and safety concerns of the study drug ....................... 66 6.6 Concomitant medications ...................................................................................... 66 6.6.1 Permitted concomitant therapy ............................................................. 66 6.6.2 Concomitant therapy requiring caution ................................................. 67 6.6.3 Prohibited concomitant therapy ............................................................ 68 6.6.4 Drugs with QT prolongation ................................................................. 68 7 Visit schedule and assessments ......................................................................................... 68 7.1 Study flow and visit schedule ................................................................................ 68 7.1.1 Screening ............................................................................................... 77 7.1.2 Treatment period ................................................................................... 78 Novartis Confidential Page 4 Amended Protocol Version 02 (Clean) Protocol No. CLEE011F2301 7.1.3 Discontinuation of Study Treatment ..................................................... 78 7.1.4 Withdrawal of Consent ......................................................................... 80 7.1.5 Follow up for Safety Evaluations .......................................................... 80 7.1.6 Efficacy follow-up ................................................................................ 81 7.1.7 Survival
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/068516 A2 24 May 20 12 (24.05.2012) W P O P C T (51) International Patent Classification: (72) Inventors; and A61K 31/352 (2006.01) A61P 25/24 (2006.01) (75) Inventors/Applicants (for US only): LETENDRE, Peter A61K 9/48 (2006.01) A61P 25/22 (2006.01) [US/US]; 2389 Indian Peaks Trail, Lafayette, Colorado A61K 9/20 (2006.01) A61P 25/00 (2006.01) 80026 (US). CARLEY, David [US/US]; 2457 Pioneer Rd., Evanston, Illinois 60201 (US). (21) International Application Number: PCT/US201 1/061490 (74) Agents: FEDDE, Kenton et al; 18325 AUenton Woods Ct, Wildwood, Missouri 63069 (US). (22) International Filing Date: 18 November 201 1 (18.1 1.201 1) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Language: English Filing AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 61/415,33 1 18 November 2010 (18. 11.2010) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (71) Applicant (for all designated States except US): PIER MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PHARMACEUTICALS [US/US]; 901 Front St., Suite OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 201, Louisville, Colorado 80027 (US).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates Et Al
    US 20150.072964A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates et al. (43) Pub. Date: Mar. 12, 2015 (54) NOVELMETHODS filed on Apr. 14, 2012, provisional application No. 61/624.293, filed on Apr. 14, 2012, provisional appli (71) Applicant: INTRA-CELLULAR THERAPIES, cation No. 61/671,713, filed on Jul. 14, 2012, provi INC., New York, NY (US) sional application No. 61/671,723, filed on Jul. 14, 2012. (72) Inventors: Sharon Mates, New York, NY (US); Robert Davis, New York, NY (US); Publication Classification Kimberly Vanover, New York, NY (US); Lawrence Wennogle, New York, (51) Int. Cl. NY (US) C07D 47L/6 (2006.01) A613 L/4985 (2006.01) (21) Appl. No.: 14/394,469 A6II 45/06 (2006.01) (52) U.S. Cl. (22) PCT Fled: Apr. 14, 2013 CPC .............. C07D 471/16 (2013.01); A61K 45/06 (2013.01); A61 K3I/4985 (2013.01) (86) PCT NO.: PCT/US13A36512 USPC ...... 514/171; 514/250; 514/211.13: 514/217; S371 (c)(1), 514/214.02: 514/220 (2) Date: Oct. 14, 2014 (57) ABSTRACT Use of particular substituted heterocycle fused gamma-car Related U.S. Application Data boline compounds as pharmaceuticals for the treatment of (60) Provisional application No. 61/624.291, filed on Apr. agitation, aggressive behaviors, posttraumatic stress disorder 14, 2012, provisional application No. 61/624,292, or impulse control disorders. US 2015/0072964 A1 Mar. 12, 2015 NOVEL METHODS One type of ICD is Intermittent Explosive Disorder (IED) which involves violence or rage. There is a loss of control CROSS REFERENCE TO RELATED grossly out of proportion to any precipitating psychosocial APPLICATIONS stresses.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Neurokinin Receptor NK Receptor
    Neurokinin Receptor NK receptor There are three main classes of neurokinin receptors: NK1R (the substance P preferring receptor), NK2R, and NK3R. These tachykinin receptors belong to the class I (rhodopsin-like) G-protein coupled receptor (GPCR) family. The various tachykinins have different binding affinities to the neurokinin receptors: NK1R, NK2R, and NK3R. These neurokinin receptors are in the superfamily of transmembrane G-protein coupled receptors (GPCR) and contain seven transmembrane loops. Neurokinin-1 receptor interacts with the Gαq-protein and induces activation of phospholipase C followed by production of inositol triphosphate (IP3) leading to elevation of intracellular calcium as a second messenger. Further, cyclic AMP (cAMP) is stimulated by NK1R coupled to the Gαs-protein. The neurokinin receptors are expressed on many cell types and tissues. www.MedChemExpress.com 1 Neurokinin Receptor Antagonists, Agonists, Inhibitors, Modulators & Activators Aprepitant Befetupitant (MK-0869; MK-869; L-754030) Cat. No.: HY-10052 (Ro67-5930) Cat. No.: HY-19670 Aprepitant (MK-0869) is a selective and Befetupitant is a high-affinity, nonpeptide, high-affinity neurokinin 1 receptor antagonist competitive tachykinin 1 receptor (NK1R) with a Kd of 86 pM. antagonist. Purity: 99.67% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg Biotin-Substance P Casopitant mesylate Cat. No.: HY-P2546 (GW679769B) Cat. No.: HY-14405A Biotin-Substance P is the biotin tagged Substance Casopitant mesylate (GW679769B) is a potent, P. Substance P (Neurokinin P) is a neuropeptide, selective, brain permeable and orally active acting as a neurotransmitter and as a neurokinin 1 (NK1) receptor antagonist.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Treatment of Depression Magdalena Burat* , Ewa Gibula-Tarlowska , Ewa Kedzierska
    DOI: 10.2478/cipms-2020-0036 Curr. Issues Pharm. Med. Sci., Vol. 33, No. 4, Pages 177-183 Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: http://www.curipms.umlub.pl/ Different molecular targets, one purpose – treatment of depression Magdalena Burat* , Ewa Gibula-Tarlowska , Ewa Kedzierska Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Poland ARTICLE INFO ABSTRACT Received 12 January 2020 Although vast scientific progress has been made, the current pharmacotherapy Accepted 04 December 2020 of depression is still not fully effective. In adults, depressive disorders are among the Keywords: most common diseases in industrialized countries, impact upon all aspects of family and depression, working life and significantly disturb social functioning. Moreover, increasingly, they antidepressants, affect children and teenagers. atypical mechanisms, novel strategies. Depressive disorders have a complex etiology. This includes a number of mechanisms that are not yet fully understood. Therefore, the current review concentrates on bringing to the foreground the many molecular areas involved in occurrence of this disease. The work highlights the notion that depression has a complex pharmacology and inevitably requires the adoption of individual pharmacotherapy. This manuscript concentrates on currently used drugs drawn from diverse therapeutic groups and presents new promising targets for the treatment of depression. This is a particularly important issue due to the continuous lack of effective therapy and the constant search for new drugs and molecular targets for its treatment. INTRODUCTION Depression and its accompanying symptoms are a – especially of monoamines, such as serotonin (5-HT), common cause of disability in the world.
    [Show full text]
  • An Open-Label, Multicenter, Expanded Access Study Of
    Clinical Development INC424 (ruxolitinib) Protocol CINC424A2401 / NCT01493414 An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post- essential thrombocythemia myelofibrosis (PET-MF) Authors Document type Amended Protocol Version EUDRACT number 2010-024473-39 Version number 05 (Clean) Development phase IIIB Document status Final Release date 21-Mar-2016 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Novartis Confidential Page 2 Amended Protocol Version 05 (Clean) Protocol No. CINC424A2401 Table of contents Table of contents .................................................................................................................2 List of figures ......................................................................................................................6 List of tables ........................................................................................................................6 List of abbreviations ............................................................................................................7 Glossary of terms...............................................................................................................10 Amendment 5 ....................................................................................................................11 Oncology clinical study protocol synopsis........................................................................39
    [Show full text]
  • WO 2011/092290 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date ι 4 August 2011 (04.08.2011) WO 201 1/092290 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 491/048 (2006.01) A61P 25/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4162 (2006.01) A61P 39/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61P 1/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/EP20 11/05 1221 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 28 January 201 1 (28.01 .201 1) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/300,231 1 February 2010 (01 .02.2010) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): NO- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (CH).
    [Show full text]
  • Clinical Study ARRAY 818 302 Array Biopharma Inc
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ncorafenib (BRAF V600-mutant inhibitor)/Binimetinib (MEK inhibitor) Array BioPharma Inc. Clinical Study ARRAY-818-302 PRINCIPAL INVESTIGATOR AGREEMENT I have read and understand the contents of the clinical protocol for Clinical Study ARRAY-818-302 dated 11 July 2019 and will adhere to the study requirements as presented, including all statements regarding confidentiality. In addition, I will conduct the study in accordance with the requirements of this protocol and also protect the rights, safety, privacy and well-being of study patients in accordance with the following: • International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guideline for Good Clinical Practice (GCP) E6(R1) • All applicable laws and regulations, including, without limitation, data privacy laws and
    [Show full text]